Treatment of a male patient suffering from drug-resistant epilepsy, resulting from a deleterious de novo sodium voltage-gated channel alpha subunit 2 (SCN2A), gene splice-site mutation, with the 5-HT precursor 5-hydroxytryptophan, led to mild clinical improvement (Horvath et al., 2016). The gene discussed is SCN2A; the disease is epilepsy.